The Dublin drugmaker on Tuesday said the planned $40 billion sale of its generics business to Teva Pharmaceutical Industries will close next month and that it will use $8 billion of the money to pay down company debt. Since the U.S. government torpedoed the merger, a deal that would have relocated Pfizer's legal domicile to Ireland to reduce Pfizer's taxes, investors have speculated Allergan might use the Teva proceeds for sizeable new deals.
Read the original:
Allergan profit beats estimates, share buybacks planned
